TABLE 2.
Multivariate analysis for survival from the first dose of mogamulizumab
| Variables | Number | Hazard ratio | (95% CI) | p value |
|---|---|---|---|---|
| Age a , years | ||||
| <70 | 54 | 1.000 | ‐ | Reference |
| >70 | 30 | 1.837 | (0.979–3.447) | 0.058 |
| Clinical subtype | ||||
| Chronic, smoldering | 8 | 1.000 | ‐ | Reference |
| Acute, lymphoma | 76 | 2.457 | (0.742–8.133) | 0.141 |
| TP53 alterations | ||||
| Absent | 49 | 1.000 | ‐ | Reference |
| Present | 35 | 2.685 | (1.427–5.050) | 0.002 |
| CD28 alterations | ||||
| Absent | 51 | 1.000 | ‐ | Reference |
| Present | 33 | 1.820 | (0.959–3.456) | 0.067 |
| Both CCR4 alterations (+) and CCR7 alterations (−) | ||||
| No | 64 | 1.000 | ‐ | Reference |
| Yes | 20 | 0.437 | (0.192–0.994) | 0.048 |
Abbreviation: CI, confidence interval.
a
age at the first dose of mogamulizumab.